Company
RS Research
A next-gen platform technology that disrupts the efficacy-toxicity trade-off with clinically validated polymer-drug conjugates for targeted chemotherapy and theranostics.
- Status
- Operatingas of 2026-09-19
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
RS Research is a clinical-stage biotechnology company discovering and developing smart nanomedicines for targeted therapies.
Funding snapshot
- Total raised
- $12MSum of rounds, as of 2026-09-19Source (opens in a new tab)
- Latest round
- Series A, $12M2021-12-15
Funding rounds
- Series A
- $12M2021-12-15, Company stated
Products
- Other
- RS-0139
- Other
- Sagitta
Loading relationship preview